Background and Purpose With proton magnetic resonance spectroscopy it is possible to measure the content of various brain metabolites in vivo, including N-acetylaspartate (which may be used as a neuronal marker), creatine, choline, and lactate. The content of these brain metabolites was measured serially from the acute stage to the chronic stage of infarction. Regional cerebral blood flow was also measured within the affected areas. These factors were compared with the clinical outcome.
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Background and Purpose With proton magnetic resonance spectroscopy it is possible to measure the content of various brain metabolites in vivo, including N-acetylaspartate (which may be used as a neuronal marker), creatine, choline, and lactate. The content of these brain metabolites was measured serially from the acute stage to the chronic stage of infarction. Regional cerebral blood flow was also measured within the affected areas. These factors were compared with the clinical outcome.
Methods Six patients with ischemic stroke were examined serially from the acute stage ( s 2 days) to the chronic stage (>6 months) with proton magnetic resonance spectroscopy. Cerebral blood flow was measured with single-photon emission-computed tomography with Tc-labeled <i,/-hexamethylenepropyleneamine oxime as flow tracer.
Results Lactate was found in all patients in the acute stage of stroke. Lactate was also found in the 3 largest lesions in the chronic stage; in 2 of these patients lactate was not found in P roton magnetic resonance spectroscopy ('H-MRS) has demonstrated its usefulness as a noninvasive research tool in the study of human brain infarction in vivo. Initially only single clinical cases examined with single-volume 'H-MRS techniques were reported. 13 These studies demonstrated reduced levels of ,/V-acetylaspartate (NAA), total creatine, and to a lesser extent the cholines as well as increased levels of lactate. Since then, several studies of smaller groups of stroke patients have been reported, confirming the initial findings. 413 Most of these studies present serial observations of patients with ischemic stroke ; however, only one study has reported serial observations stretching from the acute stage to more than 6 months after the onset of symptoms, 5 and only one previous study included measurement of cerebral blood flow within the affected areas. 10 Because NAA is almost exclusively located in neurons, 14 
-
13 it has been widely used as a neuronal marker in MRS studies of brain infarction. However, it has not yet been established the subacute stage. Reduced levels of JV-acetylaspartate were found in 5 patients; in the sixth patient with a small lesion no reduction was found. In all lesions reduced blood flow was found in the acute and chronic stage, whereas hyperemia was found in 4 patients in the subacute stage.
Conclusions In this preliminary study no clear correlation was found between the level of N-acetylaspartate or lactate in the acute stage of stroke and the clinical outcome; however, there does appear to be some connection between the reduction of cerebral blood flow and the spectroscopic findings in the chronic stage and to some extent the clinical outcome. Studies of larger clinical groups will be necessary to further elucidate the prognostic potential of proton magnetic resonance spectroscopy in human stroke. ; however, in a previous study of stroke patients lactate content was not found after 3 to 4 weeks. 9 Thus, further study of the evolution in time of lactate and NAA is needed.
In this study we present results obtained serially in six patients with brain infarction from the acute stage (<,2 days) to the chronic stage (>6 months) using singlevolume 'H-MRS and single-photon emission-computed tomography (SPECT) for measurement of regional cerebral blood flow (rCBF).
Subjects and Methods
Six patients with ischemic stroke (age range, 25 to 72 years; mean age, 52.7 years) were examined serially from the acute stage to the chronic stage ( Table 1) . Some of the data obtained in the acute stage have been published previously. 10 The study was approved by the Ethics Committee for Copenhagen and Frederiksberg municipalities, and informed consent was obtained in all cases. . At the subsequent examinations the VOI was carefully placed in the same location as previously, using the MR images as guides. Water-suppressed 'H-MRS was performed by means of a stimulated-echo acquisition mode sequence (STEAM). 16 The STEAM sequence consisted of three slice-selective 90°r adio frequency pulses, creating a stimulated echo from protons located at the intersection of the three slices in the selected VOI. Global shimming was performed with a standard nonselective shimming sequence followed by local shimming on the VOI with the STEAM sequence that was subsequently used. This resulted in a line width at half maximum for the water signal of 3 to 6 Hz. Proton spectra were obtained from the VOI at TR=1.5 seconds and TE=46, 135, and 270 milliseconds. The mixing time was 30 milliseconds, and the number of acquisitions ranged from 128 to 256. To estimate the signal loss due to incomplete T, relaxation, supplementary measurements were obtained in all patients with a TR of 6.0 seconds and a TE of 46 milliseconds. Water suppression was achieved with three 90° chemical shift-selective pulses centered on the Larmor frequency of water (with a bandwidth of 60 Hz), followed by a spoiler gradient. For each TE, the unsaturated water signal in the VOI was obtained in one acquisition by setting the amplitudes of the Gaussian watersuppression radio frequency pulses to zero. The second half of the stimulated echo was sampled by 2048 complex data points with a sample frequency of 1000 Hz. The total examination time was 1.5 to 2 hours. The time signal was corrected for eddy currents using the unsuppressed water signal as a reference. 17 The time signals were then zero-filled to 4096 data points and apodisized using a Gaussian function with a half width of 256 milliseconds. After Fourier transformation the spectra were zero-order phase corrected; no baseline correction was performed except for the purpose of presentation, when a secondorder spline function was used. The peak areas were evaluated manually with numerical integration; no fitting procedure was used. Correction for the T 2 decay was done by extrapolation of the signal versus TE to time zero using a single exponential function. 10 To estimate the concentration of NAA, total creatine, and the cholines within the lesions, the metabolite signals, corrected for T, and T 2 decay, were scaled with the unsaturated water signal corrected for T 2 decay as an internal standard, assuming a brain water concentration of 75%.'°. 18 -19 The lactate signal at TE=270 milliseconds was scaled directly with the unsaturated water signal without correction for T, and T 2 relaxation. 9 Furthermore, the following metabolite ratios were calculated at TE=270 milliseconds: NAA to choline, NAA to total creatine, choline to creatine, and lactate to choline. The calculated metabolite concentrations and ratios in the patients were compared with the values obtained from the relevant brain regions in healthy volunteers of the relevant age groups, which were recently reported in a study from our laboratory using the same method and parameters as in the present study. 19 The metabolite resonance peaks were assigned as described by Michaelis et al. 20 
Regional Cerebral Blood Flow Measurements
The rCBF was measured with a Tomomatic 232 (Medimatic a/s) brain-dedicated SPECT camera. We used 500 MBq ""Tc-labeled <i,/-hexamethylenepropyleneamine oxime ( T c -HMPAO) injected intravenously as flow tracer. Linearization correction for back-diffusion was performed, 21 and the relative rCBF within the VOI was calculated as a percentage using the contralateral symmetrically located region as reference. 10 The rCBF measurement in the acute and subacute stages was performed within 24 hours before or after the MRS examination; in the chronic stage rCBF was measured within 1 month before or after the MRS examination.
Results
The patients included in the study are listed in Table  1 , which also shows the area and size of the infarctions. Three infarctions were large (>4 cm in diameter) middle cerebral artery (MCA) infarctions, 2 were medium sized (2 to 4 cm in diameter) cortical infarctions in the parietal part of the MCA area and the occipital visual cortex, and 1 was a small (<2 cm in diameter) infarction in the putamen including parts of the internal and external capsule. The clinical data regarding the initial symptoms and findings and the findings after approximately 1 year are briefly listed in Table 1 . The time of examination after the onset of symptoms is listed in Table 2 . The calculated metabolite ratios at TE=270 milliseconds and the calculated metabolite concentrations are also shown in Table 2 . A spectrum at TE=270 milliseconds obtained from a healthy volunteer is shown in Fig 1. The results of the measurements of the relative rCBF in the affected areas are listed in Table 2 . In all patients the relative rCBF in the affected area was low in the acute stage, and in 4 patients hyperemia was found 1 week to 1 month after the onset of symptoms. The relative rCBF in the chronic stage after 7 to 17 months was similar to that in the acute stage.
In all 6 patients lactate was found within the lesions in the acute stage. In patient 1 lactate was not found in the lesion at the examinations performed 4 days and 12 days Pt indicates patient; NAA, A/-acetylaspartate; Cr, total creatine; Cho, the cholines; Lac, tactate; and rCBF, regional cerebral blood flow. *Lactate signal at TE=270 ms scaled with the unsaturated water signal (xio 4 ). 9 tLower than the 95% confidence interval for control subjects.
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*Higher than the 95% confidence interval for control subjects. 19 after the stroke, but lactate reappeared after 15 months. In patient 3 a similar pattern was seen, with lactate reappearing at the examination 7 months after stroke (Fig 2) . In patient 2 lactate was present at all three examinations (Fig 3) . In patients 4, 5, and 6 lactate disappeared between 1 week and 1 month after the onset of symptoms, and no lactate was found at the later examinations 13 to 17 months after stroke. The calcu- lated NAA concentration in the affected areas was significantly reduced (lower than the 95% confidence interval for healthy control subjects) in 5 of the patients at the examination in the chronic stage and in 4 of the patients at all examinations. In patient 6 with a small lesion the calculated NAA concentration was within the normal range at all examinations. The ratios of NAA to the cholines were reduced almost parallel with the reduction of the calculated NAA concentrations, whereas the ratios of NAA to total creatine were less sensitive as a marker of NAA loss. The calculated total creatine concentration was reduced in patients 2 and 3 at all examinations and in patients 1 and 4 at one examination. The calculated choline concentration was within the normal range at all examinations, except at one examination of patient 3. The ratio of cholines to total creatine was increased in patient 2 after 6 days but was normal at all other examinations. The calculated T, and T 2 relaxation times of NAA, total creatine, and cholines remained within the normal range for healthy volunteers 1819 - 22 from the acute stage to the chronic stage of stroke, whereas the calculated T 2 relaxation time of water was significantly longer in the chronic stage (P<.05), having increased from a mean±SD of There Is continued presence of a small lactate peak at 1.3 ppm after 1 year, whereas /V-acetyiaspartate at 2.0 ppm, total creatine at 3.0 ppm, and the chdines at 3.2 ppm are absent.
111±16 milliseconds in the acute stage to 264±122 milliseconds in the chronic stage of stroke. Discussion In the acute stage we found lactate in all 6 patients, in accordance with previously reported studies of patients with acute stroke.
2 -5 -91113 In 5 of the patients the lactate content decreased to undetectable levels after 1 to 4 weeks, as also reported previously. 9 However, in the 3 patients with large infarcts lactate was detected in the chronic stage between 7 and 15 months after the stroke incident, and in 2 of these patients lactate had surprisingly reappeared within the lesions. Several previous studies have reported findings of lactate in the chronic stage of brain infarction as late as 23 months after stroke. There is lactate present after 7 months at 1.3 ppm, although it was practically undetectabie after 16 days and 1 month. /v-Acetytaspartate is markedly reduced. similar technique, did not find lactate in any of 8 patients with chronic infarction studied between 8 months and 6 years after onset. A time course of lactate such as we found in 2 patients, with normalization followed by an increase in the chronic stage, has not previously been reported. Presence of lactate in the acute stage of brain infarction probably reflects the degree of ischemia, 9 whereas presence of lactate in the subacute/subchronic stage despite reperfusion hyperemia suggests continuing lactate production. 9 Recently Rothman et al 23 demonstrated continued lactate production in a 32-day-old infarction using MR spectroscopy. However, in a recent animal study no lactate was produced in the subacute stage of infarction. 24 In the chronic stage of infarction lactate may be produced by inflammatory and phagocytic cells that metabolize glucose mainly to lactate even under normoxic conditions. 25 Relative hypoperfusion (between 38% and 86%) in the affected areas was found in 5 of the 6 patients in the chronic stage. Although substantial loss of brain tissue in the affected area has probably occurred, which could explain the reduced blood flow, areas of relative ischemia could perhaps exist where anaerobic glycolysis and thus continued lactate production could take place; however, this is unlikely. Thus, the explanation for a biphasic time course of lactate found in 2 patients is not clear. In the 3 patients with smaller infarctions no lactate was found after 13 to 17 months, and in these patients the relative rCBF was not reduced to the same degree as in the 3 patients with large infarctions. This may in part be due to partial volume effects. Recently Hugg et al, 12 using both proton and phosphorous MRS, found alkalosis in chronic infarctions despite the presence of lactate. They suggested that one explanation may be that tissue alkalosis stimulates glycoh/sis, leading to increased tissue lactate levels, because phosphofructokinase has a high pH optimum. Among several possible explanations of tissue alkalosis Hugg et al mention "luxury perfusion"; however, we did not find elevated rCBF within the affected areas in any of our patients in the chronic stage. We did find relative hyperemia in 4 patients in the subacute stage between 7 and 30 days after the stroke, but as reported recently the method used for determination of rCBF in the present study may give rise to 10% to 30% overestimation of rCBF in the late subacute stage of stroke after day 10. 26 The content of NAA was reduced markedly in the large MCA infarctions in the chronic stage and to a lesser extent in the smaller cortical infarctions, whereas no reduction was found in the small subcortical infarction after 16 months. Because NAA is almost exclusively located in neurons, 14 -15 it would seem that the loss of neurons is largest in large infarctions. However, given the size of the VOI used, partial volume effects are unavoidable and may conceal metabolite changes in small lesions, thus probably in part explaining the finding of normal NAA content in patient 6 despite pronounced neurological deficits. The ratio of NAA to the cholines seems a little less sensitive for measurement of reductions in NAA than the semiquantitative estimation of the metabolite concentrations, and the ratio of NAA to total creatine is even less sensitive. This is due to an almost parallel reduction in the NAA and total creatine content and only marginal reduction in the choline content within the infarctions/ 10 The assumption of a brain water content of 75% may result in underestimation of the metabolite concentrations because of edema, which may increase the brain water content in the lesions 1 to 2 weeks after stroke by approximately 5% to 10%. 10 We found no significant changes in the relaxation behavior of NAA, total creatine, or cholines during the course of infarction compared with healthy volunteers.i"-
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- 27 We did find increased T 2 relaxation values of brain water in the lesions in the chronic stage, perhaps signifying an altered binding of brain water in the chronic stage. SappeyMarinier et al 8 in a recent study reported increased T 2 relaxation times of total creatine in chronic infarction; however, they reported T 2 relaxation times for NAA, total creatine, and cholines that were somewhat shorter than those previously reported. 19 -
22^7
The present study group of 6 patients is too small to draw definite conclusions regarding the prognostic information contained in a spectroscopic examination performed in the acute stage of infarction. Graham et al 3 suggested that patients with large and persistent elevations in cerebral lactate had significant neurological impairment and residual disability, whereas patients with lesser changes had a more benign clinical course. In a recent preliminary study they report significant correlation between the initial lactate and NAA measurement and the clinical outcome. 28 However, it should be emphasized that the lactate levels within an infarcted area depend on a variety of complex factors, such as rCBF, reperfusion, pH, and glucose level, and correlating outcome with the initial lactate content may therefore be an oversimplification. Ford et al, 6 in a small number of serially studied stroke patients, reported that the patients with the best recoveries had relatively preserved NAA, total creatine, and choline peaks. In the present study there does not appear to be any clear correlation between the spectroscopic findings in the acute stage of stroke and the clinical outcome. However, there does seem to be some connection between the NAA concentration measured in the chronic stage in the 3 patients with large infarctions and the relative rCBF within the lesions and to some degree with the clinical outcome. In the smaller lesions where partial volume effects may conceivably play a role, the picture is less clear. To draw more firm conclusions further stud-• ies of larger clinical groups will be necessary.
